Zhou J - Search Results

1

Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.

Qu J, Mei Q, Chen L, Zhou J. Qu J, et al. Among authors: zhou j. Cancer Immunol Immunother. 2021 Mar;70(3):619-631. doi: 10.1007/s00262-020-02735-0. Epub 2020 Oct 6. Cancer Immunol Immunother. 2021. PMID: 33025047 Free PMC article. Review.

2

[The correlation between DNA content and Fas antigen in non-small cell lung cancer].

Yu W, Zhou J, Qiu H. Yu W, et al. Among authors: zhou j. Zhonghua Jie He He Hu Xi Za Zhi. 2002 Apr;25(4):210-3. Zhonghua Jie He He Hu Xi Za Zhi. 2002. PMID: 12133327 Chinese.

3

[Expression of glucose transporter in non-small cell lung carcinoma and its clinical significance].

Lu GH, Zhong XJ, Ding W, Zhou JY. Lu GH, et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2008 Mar;37(2):176-81. doi: 10.3785/j.issn.1008-9292.2008.02.013. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2008. PMID: 18422279 Chinese.

4

[Correlation of the expression of III β-tubulin and MDR1 protein with biological features of non-small cell lung cancer].

Hu LH, Wu Y, Lu GH, Chen QY, Wang YH, Zhou JY. Hu LH, et al. Zhonghua Zhong Liu Za Zhi. 2010 Oct;32(10):762-6. Zhonghua Zhong Liu Za Zhi. 2010. PMID: 21163067 Chinese.

5

Expression and clinical significance of ezrin in non--small-cell lung cancer.

Zhang XQ, Chen GP, Wu T, Yan JP, Zhou JY. Zhang XQ, et al. Clin Lung Cancer. 2012 May;13(3):196-204. doi: 10.1016/j.cllc.2011.04.002. Epub 2011 Dec 3. Clin Lung Cancer. 2012. PMID: 22137559

6

Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.

Chen X, Zhou JY, Zhao J, Chen JJ, Ma SN, Zhou JY. Chen X, et al. Among authors: zhou jy. Anticancer Drugs. 2013 Nov;24(10):1039-46. doi: 10.1097/CAD.0000000000000011. Anticancer Drugs. 2013. PMID: 23962905

7

Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.

Pan H, Liu R, Li S, Fang H, Wang Z, Huang S, Zhou J. Pan H, et al. Among authors: zhou j. Cell Biochem Biophys. 2014 Sep;70(1):553-8. doi: 10.1007/s12013-014-9955-y. Cell Biochem Biophys. 2014. PMID: 24777808

8

MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.

Zhou JY, Chen X, Zhao J, Bao Z, Chen X, Zhang P, Liu ZF, Zhou JY. Zhou JY, et al. Cancer Lett. 2014 Sep 1;351(2):265-71. doi: 10.1016/j.canlet.2014.06.010. Epub 2014 Jun 28. Cancer Lett. 2014. PMID: 24983493

9

Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer.

Zhou J, Yao H, Zhao J, Zhang S, You Q, Sun K, Zou Y, Zhou C, Zhou J. Zhou J, et al. Among authors: zhou c. Histopathology. 2015 Jun;66(7):949-54. doi: 10.1111/his.12560. Epub 2015 Feb 5. Histopathology. 2015. PMID: 25257756

10

[Clinicopathological features associated with EGFR gene mutation in non-small cell lung cancer patients].

Zhou J, Mo W, Zhao J, Zheng J, Ding W, Zhou J. Zhou J, et al. Zhonghua Yi Xue Za Zhi. 2014 Aug 13;94(30):2332-6. Zhonghua Yi Xue Za Zhi. 2014. PMID: 25399972 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55,459 results

Search Page

Filters